1. Home
  2. DSU vs RLMD Comparison

DSU vs RLMD Comparison

Compare DSU & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Blackrock Debt Strategies Fund Inc.

DSU

Blackrock Debt Strategies Fund Inc.

HOLD

Current Price

$9.71

Market Cap

605.4M

Sector

Finance

ML Signal

HOLD

Logo Relmada Therapeutics Inc.

RLMD

Relmada Therapeutics Inc.

HOLD

Current Price

$6.50

Market Cap

661.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DSU
RLMD
Founded
N/A
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Finance Companies
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
605.4M
661.9M
IPO Year
1998
2012

Fundamental Metrics

Financial Performance
Metric
DSU
RLMD
Price
$9.71
$6.50
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$12.40
AVG Volume (30 Days)
311.2K
2.4M
Earning Date
01-01-0001
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
45.28
EPS
N/A
N/A
Revenue
N/A
$13,070.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
154.83
52 Week Low
$9.31
$0.55
52 Week High
$10.64
$8.00

Technical Indicators

Market Signals
Indicator
DSU
RLMD
Relative Strength Index (RSI) 48.28 47.38
Support Level $9.61 $6.17
Resistance Level $9.77 $7.28
Average True Range (ATR) 0.06 0.42
MACD 0.01 -0.00
Stochastic Oscillator 49.92 41.20

Price Performance

Historical Comparison
DSU
RLMD

About DSU Blackrock Debt Strategies Fund Inc.

Blackrock Debt Strategies Fund Inc is a closed-end management investment company. Its primary investment objective is to seek to provide current income by investing in a diversified portfolio of U.S. companies debt instruments, including senior and subordinated corporate loans, both secured and unsecured, which are rated in the lower rating categories of the established rating services or unrated debt instruments, which are in the judgment of the investment adviser of equivalent quality. The Fund may invest directly in debt instruments or synthetically through the use of derivatives. The Fund's secondary investment objective is to seek to provide capital appreciation.

About RLMD Relmada Therapeutics Inc.

Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.

Share on Social Networks: